BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30324188)

  • 1. Glycyrrhetinic acid as a hepatocyte targeting unit for an anticancer drug delivery system with enhanced cell type selectivity.
    Singh H; Kim SJ; Kang DH; Kim HR; Sharma A; Kim WY; Kang C; Kim JS
    Chem Commun (Camb); 2018 Oct; 54(87):12353-12356. PubMed ID: 30324188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
    Zhang J; Zhang M; Ji J; Fang X; Pan X; Wang Y; Wu C; Chen M
    Pharm Res; 2015 Oct; 32(10):3376-90. PubMed ID: 26148773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy.
    Cai Y; Xu Y; Chan HF; Fang X; He C; Chen M
    Mol Pharm; 2016 Mar; 13(3):699-709. PubMed ID: 26808002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.
    Chen F; Zhang J; He Y; Fang X; Wang Y; Chen M
    Biomater Sci; 2016 Jan; 4(1):167-82. PubMed ID: 26484363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier.
    Lv Y; Li J; Chen H; Bai Y; Zhang L
    Int J Nanomedicine; 2017; 12():4361-4370. PubMed ID: 28652738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma.
    Xu Y; Wang M; Ning S; Yang Z; Zhou L; Xia X
    Molecules; 2022 Oct; 27(20):. PubMed ID: 36296377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid.
    Li J; Xu H; Ke X; Tian J
    J Drug Target; 2012 Jun; 20(5):467-73. PubMed ID: 22577855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced targeted delivery of adenine to hepatocellular carcinoma using glycyrrhetinic acid-functionalized nanoparticles in vivo and in vitro.
    Wu F; Xue H; Li X; Diao W; Jiang B; Wang W; Yu W; Bai J; Wang Y; Lian B; Feng W; Sun T; Qu M; Zhao C; Wang Y; Wu J; Gao Z
    Biomed Pharmacother; 2020 Nov; 131():110682. PubMed ID: 32947204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycyrrhetinic Acid as a Hepatocyte Targeting Ligand-Functionalized Platinum(IV) Complexes for Hepatocellular Carcinoma Therapy and Overcoming Multidrug Resistance.
    Huang X; Li G; Li H; Zhong W; Jiang G; Cai J; Xiong Q; Wu C; Su K; Huang R; Xu S; Liu Z; Wang M; Wang H
    J Med Chem; 2024 May; 67(10):8020-8042. PubMed ID: 38727048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A glycyrrhetinic acid-iridium(III) conjugate as a theranostic NIR probe for hepatocellular carcinoma with mitochondrial-targeting ability.
    Wang L; Wang X; Chen F; Song YQ; Nao SC; Chan DS; Wong CY; Wang W; Leung CH
    Eur J Med Chem; 2024 Jan; 264():115995. PubMed ID: 38043488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in Asialoglycoprotein Receptor and Glycyrrhetinic Acid Receptor-Mediated and/or pH-Responsive Hepatocellular Carcinoma- Targeted Drug Delivery.
    Li YL; Zhu XM; Liang H; Orvig C; Chen ZF
    Curr Med Chem; 2021; 28(8):1508-1534. PubMed ID: 32368967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cleavable Multifunctional Targeting Mixed Micelles with Sequential pH-Triggered TAT Peptide Activation for Improved Antihepatocellular Carcinoma Efficacy.
    Zhang J; Zheng Y; Xie X; Wang L; Su Z; Wang Y; Leong KW; Chen M
    Mol Pharm; 2017 Nov; 14(11):3644-3659. PubMed ID: 28994600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
    Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N
    Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular uptake mechanism and clearance kinetics of fluorescence-labeled glycyrrhetinic acid and glycyrrhetinic acid-modified liposome in hepatocellular carcinoma cells.
    Sun Y; Lu J; Yan D; Shen L; Hu H; Chen D
    Environ Toxicol Pharmacol; 2017 Jul; 53():46-56. PubMed ID: 28501784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytes.
    Jang JW; Song Y; Kim KM; Kim JS; Choi EK; Kim J; Seo H
    BMC Cancer; 2016 Oct; 16(1):810. PubMed ID: 27756242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-Targeted Lactoferrin Shell-Oily Core Nanocapsules for Synergistic Targeted/Herbal Therapy of Hepatocellular Carcinoma.
    Abdelmoneem MA; Elnaggar MA; Hammady RS; Kamel SM; Helmy MW; Abdulkader MA; Zaky A; Fang JY; Elkhodairy KA; Elzoghby AO
    ACS Appl Mater Interfaces; 2019 Jul; 11(30):26731-26744. PubMed ID: 31268657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycyrrhetinic Acid triggers a protective autophagy by activation of extracellular regulated protein kinases in hepatocellular carcinoma cells.
    Tang ZH; Li T; Chang LL; Zhu H; Tong YG; Chen XP; Wang YT; Lu JJ
    J Agric Food Chem; 2014 Dec; 62(49):11910-6. PubMed ID: 25403108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes.
    Sun Y; Dai C; Yin M; Lu J; Hu H; Chen D
    Int J Nanomedicine; 2018; 13():1621-1632. PubMed ID: 29588589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced delivery of doxorubicin to the liver through self-assembled nanoparticles formed via conjugation of glycyrrhetinic acid to the hydroxyl group of hyaluronic acid.
    Wang X; Gu X; Wang H; Yang J; Mao S
    Carbohydr Polym; 2018 Sep; 195():170-179. PubMed ID: 29804965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodistribution and biocompatibility of glycyrrhetinic acid and galactose-modified chitosan nanoparticles as a novel targeting vehicle for hepatocellular carcinoma.
    Li M; Wang Y; Jiang S; Gao Y; Zhang W; Hu S; Cheng X; Zhang C; Sun P; Ke W; Wang G; Song Z; Zhang Y; Zheng QC
    Nanomedicine (Lond); 2020 Jan; 15(2):145-161. PubMed ID: 31782335
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.